| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/05/2008 | WO2008064592A1 A composition comprising chinese traditional medicine as active ingredient for treating cardiovascular diseases and quality control method thereof |
| 06/05/2008 | WO2008064558A1 Bromo-dihydroartemisinin and its preparation |
| 06/05/2008 | WO2008064487A1 Method for in situ solidification of blood-polymer compositions for regenerative medicine and cartilage repair applications |
| 06/05/2008 | WO2008064475A1 Burn bandage |
| 06/05/2008 | WO2008064474A1 Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 06/05/2008 | WO2008064432A1 Polycyclic molecular compounds |
| 06/05/2008 | WO2008064425A1 Glycoalkaloid and chemotherapeutic agent combinations and various uses thereof |
| 06/05/2008 | WO2008064393A1 Treatment for envenomation |
| 06/05/2008 | WO2008048801A3 Phenylalkylamino carbamate compositions |
| 06/05/2008 | WO2008048469A3 Controlled-release coated dosage forms containing galantamine |
| 06/05/2008 | WO2008045378A3 Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin |
| 06/05/2008 | WO2008045377A3 High-purity large-scale preparation of stannsoporfin |
| 06/05/2008 | WO2008044144A3 Chiral tetra-hydro beta-carbolic derivatives and applications thereof as antiparasitic compounds |
| 06/05/2008 | WO2008043791A3 Thiophene derivatives for treating hepatitis c |
| 06/05/2008 | WO2008043788A3 Novel compounds |
| 06/05/2008 | WO2008043740A8 Use of lansoprazole for the treatment of frequent heartburn |
| 06/05/2008 | WO2008043075A3 Compositions for the treatment of scleritis |
| 06/05/2008 | WO2008042921A3 Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use |
| 06/05/2008 | WO2008042240A3 Enantiomerically pure phosphoindoles as hiv inhibitors |
| 06/05/2008 | WO2008039409A8 Methods and kits for use in the treatment and prevention of diseases or conditions of the immune system or infectious diseases |
| 06/05/2008 | WO2008037257A3 Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| 06/05/2008 | WO2008035228A3 2- substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof |
| 06/05/2008 | WO2008035206A3 2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin d3 analogs and uses thereof |
| 06/05/2008 | WO2008034909A3 Second line treatment of metastatic hormone refractory prostate cancer using satraplatin |
| 06/05/2008 | WO2008034621A3 Nucleotide phosphorylase for the prophylaxis, treatment or diagnosis of acute lung injury (ali) |
| 06/05/2008 | WO2008024765B1 Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds |
| 06/05/2008 | WO2008024027A3 Use of 9-oxoacridine-10-acetic acid, its salts and esters for enhancing the efficacy of antiandrogenic treatment |
| 06/05/2008 | WO2008017473A3 Structure and use of 5' phosphate oligonucleotides |
| 06/05/2008 | WO2008012782A3 Labelled analogues of halobenzamides as radiopharmaceuticals |
| 06/05/2008 | WO2008012645A3 Use of vitamin d3 agonist in a mammalian model for atopic diseases and of vitamin d3 antagonists for the treatment of atopic diseases |
| 06/05/2008 | WO2008006581A3 Compositions and use thereof for the treatment, co-treatment or prevention of imflammatory disorders |
| 06/05/2008 | WO2008005295A3 Modulators of muscarinic receptors |
| 06/05/2008 | WO2008001200A3 Transdermal composition having enhanced color stability |
| 06/05/2008 | WO2007146747A3 Pas kinase regulates energy homeostasis |
| 06/05/2008 | WO2007141530A3 Treatment of excess sebum production |
| 06/05/2008 | WO2007132418B1 The use of the salicylate as an antidote for paraquat intoxications in mammals |
| 06/05/2008 | WO2007128588A3 Glutadon |
| 06/05/2008 | WO2007118130A3 Antibacterial agents |
| 06/05/2008 | WO2007115805A3 Aurora kinase inhibitors |
| 06/05/2008 | WO2007112322A3 Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
| 06/05/2008 | WO2007107442A3 Bis1,2,3,4-tetrahydroisoquinoline derivatives and their uses as pharmaceuticals |
| 06/05/2008 | WO2007107246A3 SUBSTITUTED 2-AMINO-4-PHENYL-DιHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM |
| 06/05/2008 | WO2007103839A3 Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors |
| 06/05/2008 | WO2007098240B1 Compositions to reduce blood glucose levels and treat diabetes |
| 06/05/2008 | WO2007087129A3 Fluorinated arylamide derivatives |
| 06/05/2008 | WO2007084135A3 Inhibitors of checkpoint kinases |
| 06/05/2008 | WO2007073178A3 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition |
| 06/05/2008 | WO2007065288A3 Useful combinations of monobactam antibiotics with beta-lactamase inhibitors |
| 06/05/2008 | WO2007059106A3 Administration of mntor inhibitor to treat patients with cancer |
| 06/05/2008 | WO2007050585A3 Use of a nitric oxide synthase modulator for the treatment of cardiac indications |
| 06/05/2008 | WO2007035405A3 In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein |
| 06/05/2008 | US20080132978 Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| 06/05/2008 | US20080132963 Method and apparatus for treating tumors using low strength electric fields |
| 06/05/2008 | US20080132830 Separable solid dosage form administration system |
| 06/05/2008 | US20080132706 Compounds as PDE IV and TNF Inhibitors |
| 06/05/2008 | US20080132704 3-Substituted quinuclidines and their use |
| 06/05/2008 | US20080132699 Process For the Preparation of Diazine Derivatives |
| 06/05/2008 | US20080132678 Such as N-(4-morpholine)carbonyl-(O-benzyl)-L-tyrosine-L-leucine boronic acid for reducing rate of degradation of proteins; proteasome inhibitors |
| 06/05/2008 | US20080132585 Separate type medical material |
| 06/05/2008 | US20080132582 Propofol formulation containing reduced oil and surfactants |
| 06/05/2008 | US20080132581 particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae |
| 06/05/2008 | US20080132580 Dispersion For Delivering Active Agents |
| 06/05/2008 | US20080132579 characterized by at least one of an enantiomeric excess of at least about 99.8%; having less than about 1700 ppm of residual C1-C4 alcohol; or having a pH of at least about 4.3 in 1% aqueous solution at room temperature |
| 06/05/2008 | US20080132578 venlafaxine metabolites used for treating and preventing psychological disorders, Parkinson's disease, epilepsy, obesity, incontinence or Alzheimer's disease; side effect reduction |
| 06/05/2008 | US20080132577 N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide its hydrates, crystalline forms and addition salts; agonist of receptors of the melatoninergic system and an antagonist of the 5-HT2C receptor; treats genetic disorder characterized by a specific pattern of physical, behavioral, and developmetnal features |
| 06/05/2008 | US20080132576 1-(3-chloro-2-fluorobenzyl)-3-(2-hydroxyethyl)-thiourea; analgesics; gastrointestinal disorders, chronic pain, glaucoma, vision defects; rheumatoid arthritis, spondylitis, gouty arthritis, osteoarthritis, juvenile arthritis; autoimmune diseases: lupus erythematosus |
| 06/05/2008 | US20080132575 specific dissolution profile; specific particle size distribution |
| 06/05/2008 | US20080132574 Leukotriene B4 receptor binding activity; treatment of skin disease such as psoriasis, eczema, skin cancer, keratosis, dyspigmentation or psilosis |
| 06/05/2008 | US20080132573 ricinoleic acid derivatives; transient receptor potential vanilloid (cannabinoid receptor) agonist; neuroprotective effect against glutamate excitotoxicity, antiemetic; urinary incontinence, for the relief of neuropathic pain, intestinal inflammatory disorders |
| 06/05/2008 | US20080132571 Nutrient Sensor |
| 06/05/2008 | US20080132570 Levodopa prodrugs, and compositions and uses thereof |
| 06/05/2008 | US20080132568 vitamin E oxidation product alpha -tocopherylquinone derivatives; anticarcinogenic, antitumor, antiproliferative agent; prostate cancer, benign prostatic hyperplasia, androgenic alopecia, hirsutism, acne, seborrhea, adrenal hyperplasia, precocious puberty, and polycystic ovary syndrome |
| 06/05/2008 | US20080132567 Alpha-Aminoamide Derivatives Useful in the Treatment of Lower Urinary Tract Disorders |
| 06/05/2008 | US20080132566 Metabolic Syndrome-Improving Agent and Medicine, Supplement, Functional Food and Food Additive Containing the Same |
| 06/05/2008 | US20080132565 Polycyclic Macrolactones |
| 06/05/2008 | US20080132564 Micellar drug delivery vehicles and precursors thereto and uses thereof |
| 06/05/2008 | US20080132563 1-Thio-D-Glucitol Derivatives |
| 06/05/2008 | US20080132562 Tetronic and tetramic acids |
| 06/05/2008 | US20080132561 Materials and Methods for Treating Hypercholesterolemia |
| 06/05/2008 | US20080132560 fluvastatin sodium and a polymer in a solidified form of an at least partially liquid dispersion solution; allows a zero-order drug release over a prolonged period of time |
| 06/05/2008 | US20080132559 2-(2-aminobenzoyl)-N-2-nitro-4-methylsulfonyl-phenylethylamine; glycogen synthase kinase-3 (GSK3 beta inhibitor and NMDA channel modulator; neurodegenerative diseases, type II diabetes, anticarcinogenic agent |
| 06/05/2008 | US20080132557 Heterocyclic Carboxamides with Microbiocidal Activity |
| 06/05/2008 | US20080132556 3-hydroxymethyl-4hydroxy-phenyl- derivatives for the treatment of respiratory diseases |
| 06/05/2008 | US20080132555 Preparation and utility of substituted phenyltetrazoles |
| 06/05/2008 | US20080132554 Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| 06/05/2008 | US20080132553 Preventing and reversing the formation of advance glycosylation endproducts |
| 06/05/2008 | US20080132552 e.g. N-[1-(3,5-Difluoro-benzyl)-2-hydroxy-3-methylamino-propyl]-5-methyl-N',N'-dipropyl-isophthalamide; beta-secretase inhibitor; neurodegenerative diseases: Alzheimer's disease |
| 06/05/2008 | US20080132551 Positive allosteric modulators of the nicotinic acetylcholine receptor |
| 06/05/2008 | US20080132550 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease |
| 06/05/2008 | US20080132549 Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids |
| 06/05/2008 | US20080132548 Certain chemical entities, compositions, and methods |
| 06/05/2008 | US20080132547 (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2 -pyridinyl)methyl)sulfinyl)-1H-benzimidazole, (R(+)-lansoprazole); antiulcer agent |
| 06/05/2008 | US20080132546 e.g. Methyl 2-(6-{[(ethylamino)carbonyl]amino}pyridin-3-yl)-1,3-thiazole-5-carboxylate; bacterial DNA gyrase or bacterial topoisomerase IV inhibitor; antibacterial agent; antibiotic resistance; skin structure infections, pneumoniae, bronchitis, acute sinusitis, otitis media, sepsis, osteomyelitis |
| 06/05/2008 | US20080132545 Certain chemical entities, compositions, and methods |
| 06/05/2008 | US20080132544 Peroxisome Proliferator-Activated Receptor Ligand |
| 06/05/2008 | US20080132543 Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists |
| 06/05/2008 | US20080132542 [5-(5-{4-[2-(Trifluoromethyl)phenoxy]piperidin-1-yl}-1,3,4-thiadiazol-2-yl)-2H-tetrazol-2-yl]acetic acid; metabolic disorders,antidiabetic, hypoglycemic agent; obesity, insulin resistance, liver steatosis, atherosclerosis, neurological disease, dyslipidemia, hyperlipidemia, low HDL, and high LDL |
| 06/05/2008 | US20080132541 immunomodulatory compound is administered in combination with a therapy conventionally used to treat, prevent or manage cancer; potent inhibition of TNF- alpha but also marked inhibition of LPS |
| 06/05/2008 | US20080132540 Such as trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide; for treating/preventing anxiolytic disorders/depression, injured mammalian nerve tissue, conditions, neurological disorders, bone loss, substance related disorders, and obesity; neuropeptide y (NPY Y2) |
| 06/05/2008 | US20080132539 e.g. 2-amino-5-[(naphthalen-1-ylmethyl)-aminocarbonyl]-pentanoic acid hydroxyamide; advanced glycosylation endproducts inhibitor; diabetic neurosis, diabetic retinopathy, atherosclerosis, cataract, Alzheimer's disease, rheumatic arthritis, osteoarthritis, chronic renal failure; food and cosmetics |